Having trouble accessing articles? Reset your cache.

Biogen plotting next steps in lupus after latest readout

As Biogen seeks to build its immunology franchise, it became the latest company to post encouraging data in lupus, with BIIB059 meeting the primary endpoints in a Phase II trial to treat both cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE).

Biogen Inc. (NASDAQ:BIIB) said Tuesday that all three doses of BIIB059, a mAb targeting CLEC4C,

Read the full word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE